

December 20, 2017

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached Press Release issued by the Company titled:


“Strides Shasun acquires controlling stake in Trinity Pharma, South Africa”

Also, enclosed is the disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 on the said acquisition.

Thanks & Regards,
For **STRIDES SHASUN LIMITED**



Manjula Ramamurthy
Company Secretary



Encl: As above



Press Release

December 20, 2017

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun acquires controlling stake in Trinity Pharma, South Africa

Acquisition expands Strides' presence from West & East Africa to South Africa

Bangalore, December 20, 2017, Strides Pharma Asia Pte Ltd., Singapore, a wholly owned subsidiary of Strides Shasun Limited has entered into definitive agreements with Trinity Pharma Proprietary Limited, South Africa (Trinity) for acquisition of controlling stake in Trinity.

Strategic Rationale:

- The transaction allows Strides to establish a presence in the high entry barrier market of South Africa where product dossier approval takes more than 5 years.
- Provides access to pipeline of more than 110 product dossiers already submitted.
- Acquisition comes with proven management and expertise in business development, marketing & regulatory services.
- Will be an important platform for Strides' ARV launch in the large, private non-tender market in South Africa.
- Provides established distribution channel for faster commercialization of existing products of Strides, already registered in South Africa.

Transaction Details:

- Under the terms of the agreement, Strides Pharma Asia Pte Ltd., Singapore will acquire 55% stake in Trinity for a cash consideration of South African Rand 55 Million (approximately INR 27.5 Crores).
- The current management will stay as minority partner and will continue to run the business under the supervision of Strides.
- The transaction is subject to customary closing conditions including approval from the South African regulatory authority, Transaction Regulation Panel and expected to close on or before January 5, 2018.

Shashank Sinha, Managing Director of Strides Shasun Limited said "The acquisition provides further impetus to our 'In Africa For Africa' strategy as it fast tracks Strides presence in the lucrative and high entry barrier market of South Africa. With this acquisition, we are now present in East, West and South Africa, covering all the key markets in Sub Saharan Africa."



About Trinity Pharma Proprietary Limited, South Africa

Trinity, founded in 2003, is engaged in the business of supply and distribution of generic pharmaceutical products to pharmaceutical retailers and providing services relating to regulatory and registration of products. It also acts as holder of Certificate of Registration for clients. The manufacturing of its product portfolio is outsourced. Trinity posted a turnover of South African Rand 76.4 Million for the year ended February 2017.


About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has three business verticals, viz., Regulated Markets, Emerging Markets and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at www.stridesarco.com


For further information, please contact:

<p>Strides Shashank Sinha, Managing Director +91 80 6784 0335</p> <p>Investors: Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid: +91 80 6784 0791</p> <p>Strides Shasun Limited CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector – 17, Vashi, Navi Mumbai – 400 703 Email: investors@stridesshasun.com</p>	<p>PR Consultancy Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.in</p> <p>K Priya: +91 9535425418 priya@fortunapr.in</p>
---	---



**Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sr. No	Particulars	Description
1.	Name of the Target entity, details in brief such as size, turnover etc.	Trinity Pharma Proprietary Limited is a Private Company incorporated under the laws of Republic of South Africa. The total paid up capital of Trinity is 1,360 ordinary equity shares of par value INR 5/- each approx. (South African Rand 1/-).*
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	No
3.	Industry to which Target entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition	Proposed Transaction will enable in: <ul style="list-style-type: none"> • Market entry into high entry barrier market of South Africa where product dossier approval takes more than 5 years. • Access to pipeline of more than 110 product dossiers submitted till Aug'17. • Existing set-up of business with proven expertise in BD, Marketing & Regulatory services. • Will enable Strides ARV launch in private non-tender market.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Approval from the South African regulatory authority, Transaction Regulation Panel.
6.	Indicative time period for completion	30 days
7.	Nature of consideration	Cash
8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	55% equity stake (748 shares)
9.	Cost of acquisition or the price at which the shares are acquired	INR 27.5 crores approximately (South African Rand 55 million)*



10.	Brief background about entity acquired in terms of:		
a.	Products/line of business acquired	Pharmaceuticals	
b.	Date of incorporation	2003	
c.	History of last 3 years turnover	Calendar year	Turnover (in South African Rand Mn)*
		Mar 14 to Feb 15	18.2
		Mar 15 to Feb 16	40.7
		Mar 16 to Feb 17	76.4
d.	Country in which the acquired entity has presence	South Africa	
e.	Any other significant information	The acquisition is being made by Strides Pharma Asia Pte Limited, Singapore, a wholly owned subsidiary of Strides Shasun Limited.	

**Note: Currency Exchange Rate: 1 South African Rand = 5 INR*

